Sign inGet started

Shah Smital

Insider CIK 1808821 · PLRX Director · LYEL Chief Fin. and Bus. Officer · GRPH Director

Track record PRO

XXXX$█.██M██+██%
XXXX$█.██M██+██%
XXXX$█.██M██+██%
Track record
See how this insider's past purchases performed 30 and 90 days later, and a conviction score on each buy.
Upgrade to Pro · $99/yearAlready Pro? Log in

Trades across companies

TickerCodeTradeFiledSharesPriceValueOwned after
LYEL Lyell Immunopharma, Inc. A Award deriv2026-03-092026-03-16140,000— $0140,000SEC↗
PLRX PLIANT THERAPEUTICS, INC. A Award deriv2024-06-132024-06-1726,764— $026,764SEC↗
GRPH Graphite Bio, Inc. A Award deriv2023-07-192023-07-2120,000— $020,000SEC↗
PLRX PLIANT THERAPEUTICS, INC. A Award deriv2023-06-072023-06-0814,000— $014,000SEC↗
GRPH Graphite Bio, Inc. A Award deriv2022-06-212022-06-2220,000— $020,000SEC↗
PLRX PLIANT THERAPEUTICS, INC. A Award deriv2022-06-162022-06-2115,000— $015,000SEC↗
GRPH Graphite Bio, Inc. P Buy2021-06-292021-07-015,882$17.00 $100.0K5,882SEC↗
PLRX PLIANT THERAPEUTICS, INC. A Award deriv2021-06-292021-06-3013,286— $013,286SEC↗
GRPH Graphite Bio, Inc. A Award deriv2021-04-152021-07-0193,585— $093,585SEC↗